Why Fennec Pharmaceuticals Inc.’s (FENC) Stock Is Down 7.67%
As of Wednesday, August 12, Fennec Pharmaceuticals Inc.’s FENC share price has dipped by 7.67%, which has investors questioning if this is right time to buy.Rosalio Madrigal
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. The company’s product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of cisplatin-induced ototoxicity pediatric patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. Fennec Pharmaceuticals Inc. has collaboration with Tampa General Hospital Foundation, Inc. for evaluation of clinical utility of sodium thiosulfate injection in reducing the risk of ototoxicity in adolescent, young adult, and adult cancer patients receiving cisplatin-based treatment; and Norgine Pharma UK Limited. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.
Commentary & Analysis
Why Fennec Pharmaceuticals Inc.’s (FENC) Stock Is Up 12.98%
As of Tuesday, August 11, Fennec Pharmaceuticals Inc.’s FENC share price has surged by 12.98%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Fennec Pharmaceuticals Inc.’s (FENC) Stock Is Up 8.23%
As of Tuesday, August 11, Fennec Pharmaceuticals Inc.’s FENC share price has surged by 8.23%, which has investors questioning if this is right time to sell.Michael Rose
Why Fennec Pharmaceuticals Inc.’s (FENC) Stock Is Down 5.05%
As of Monday, August 10, Fennec Pharmaceuticals Inc.’s FENC share price has dipped by 5.05%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Fennec Pharmaceuticals Inc.’s (FENC) Stock Is Up 5.04%
As of Wednesday, August 05, Fennec Pharmaceuticals Inc.’s FENC share price has surged by 5.04%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Financial Summary
| Share Statistics | FENC | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $397.3 | $286.3 | 34% |
|
| Shares Out (Mil) | 36.4 | 54.2 | 40% |
|
| Institutional Ownership | 86.4% | 92.8% | 54% |
|
| Float (Mil) | 19.8 | 39.7 | 29% |
|
| Beta | 1.07 | 0.94 | 65% |
|
| Avg Daily Volume (000s) | 265 | 534 | 48% |
|
| Price Change (52-week) |
43.2% | 58.7% | 76% |
|
| Growth | FENC | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 194.9% | 13.6% | 100% |
|
| Net Income (5yr) | 11.7% | (10.1%) | 58% |
|
| EPS (5yr) | 14.9% | 16.0% | 55 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (12.5%) | (15.6%) | 57% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 5 | 5 | 5 | |
| Current EPS | $0.114 | $0.334 | $0.952 | |
| Month Ago EPS | $0.125 | $0.296 | $0.890 | |
| # Rev Up | 0 | 0 | 1 | |
| # Rev Down | 1 | 2 | 0 | |
| Three Months Ago EPS | $0.134 | $0.312 | $1.038 | |
| Year/Year Chg | 128.0% | (197.9%) | (530.2%) | |
| Financials | FENC | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $59 | $37 | 21% |
|
| Net Income (TTM) (Mil) | ($3) | ($43) | 35% |
|
| EPS (TTM) | ($0.101) | ($1.400) | 36% |
|
| Operating Cash Flow (TTM) (Mil) | ($2) | ($31) | 29% |
|
| Net Cash Flow (TTM) (Mil) | na | $2 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $4 | 0% |
|
| Enterprise Value (Q1) (Mil) | $370 | $160 | 32% |
|
| Valuation | FENC | Industry Median |
Percentile (All Stocks) |
|
| P/B | 9.36 | 2.77 | 89% |
|
| P/E | na | 19.1 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | FENC | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 93.7% | 64.2% | 95% |
|
| Net Margin | (5.5%) | (75.9%) | 25% |
|
| ROA | (5.4%) | (47.3%) | 29% |
|
| ROE | (18.6%) | (55.0%) | 24% |
|
| Liabilities to Assets | 44.0% | 29.6% | 35% |
|
| F-Score | 6 | 2 | 67% |
|
Fennec Pharmaceuticals Inc. did not pass any screens on 8/20/2026.
